HK1250991A1 - Iii型分泌系統靶向分子 - Google Patents

Iii型分泌系統靶向分子

Info

Publication number
HK1250991A1
HK1250991A1 HK18110279.1A HK18110279A HK1250991A1 HK 1250991 A1 HK1250991 A1 HK 1250991A1 HK 18110279 A HK18110279 A HK 18110279A HK 1250991 A1 HK1250991 A1 HK 1250991A1
Authority
HK
Hong Kong
Prior art keywords
type iii
targeting molecules
secretion system
iii secretion
system targeting
Prior art date
Application number
HK18110279.1A
Other languages
English (en)
Inventor
Andrew Hollands
John C Timmer
Quinn Deveraux
Brendan P Eckelman
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of HK1250991A1 publication Critical patent/HK1250991A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18110279.1A 2015-05-01 2018-08-10 Iii型分泌系統靶向分子 HK1250991A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155967P 2015-05-01 2015-05-01
US201562254992P 2015-11-13 2015-11-13
PCT/US2016/030429 WO2016179101A2 (en) 2015-05-01 2016-05-02 Type iii secretion system targeting molecules

Publications (1)

Publication Number Publication Date
HK1250991A1 true HK1250991A1 (zh) 2019-01-18

Family

ID=57205652

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110279.1A HK1250991A1 (zh) 2015-05-01 2018-08-10 Iii型分泌系統靶向分子

Country Status (16)

Country Link
US (2) US10344078B2 (zh)
EP (1) EP3288974B1 (zh)
JP (1) JP6966330B2 (zh)
KR (1) KR20180020142A (zh)
CN (1) CN107922482A (zh)
AU (1) AU2016257751B2 (zh)
BR (1) BR112017023378A2 (zh)
CA (1) CA2984628C (zh)
ES (1) ES2846881T3 (zh)
HK (1) HK1250991A1 (zh)
IL (1) IL255329B (zh)
MX (1) MX2017014002A (zh)
NZ (1) NZ736776A (zh)
RU (1) RU2759949C2 (zh)
WO (1) WO2016179101A2 (zh)
ZA (1) ZA201707404B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013337A2 (pt) * 2019-01-07 2021-11-09 Bactolife Aps Proteínas de ligação a patógenos
MX2021013417A (es) 2019-05-04 2021-12-10 Inhibrx Inc Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
KR20220031549A (ko) * 2019-05-08 2022-03-11 2세븐티 바이오, 인코포레이티드 Cll-1 표적화 면역요법
CN115003693A (zh) * 2019-12-20 2022-09-02 加拿大商木曾路生物科技公司 多肽、蛋白质复合物及其制造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094951A (en) * 1988-06-21 1992-03-10 Chiron Corporation Production of glucose oxidase in recombinant systems
AU3243199A (en) * 1998-03-05 1999-09-20 University Of British Columbia, The Methods for assaying type iii secretion inhibitors
AU2005323025A1 (en) * 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
CN102517280A (zh) * 2007-01-31 2012-06-27 菲尼克斯股份有限公司 用于提高表达的细菌前导序列
WO2009073631A2 (en) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2010107778A1 (en) * 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
CA2784033A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
EP2655402A1 (en) * 2010-12-23 2013-10-30 Intercell Austria AG Oprf/i agents and their use in hospitalized and other patients
JP6182152B2 (ja) * 2011-11-07 2017-08-16 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
JP2014533249A (ja) 2011-11-07 2014-12-11 メディミューン,エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules

Also Published As

Publication number Publication date
US10344078B2 (en) 2019-07-09
IL255329A0 (en) 2017-12-31
RU2759949C2 (ru) 2021-11-19
IL255329B (en) 2021-09-30
RU2017141738A (ru) 2019-06-03
US20190345235A1 (en) 2019-11-14
RU2017141738A3 (zh) 2020-05-22
CN107922482A (zh) 2018-04-17
AU2016257751B2 (en) 2021-01-21
EP3288974A2 (en) 2018-03-07
ES2846881T3 (es) 2021-07-30
WO2016179101A3 (en) 2016-12-15
JP6966330B2 (ja) 2021-11-17
AU2016257751A1 (en) 2017-11-16
CA2984628A1 (en) 2016-11-10
MX2017014002A (es) 2018-08-01
ZA201707404B (en) 2021-06-30
US10745466B2 (en) 2020-08-18
KR20180020142A (ko) 2018-02-27
EP3288974A4 (en) 2018-10-24
NZ736776A (en) 2024-08-30
EP3288974B1 (en) 2020-11-04
CA2984628C (en) 2023-09-05
US20160318996A1 (en) 2016-11-03
WO2016179101A2 (en) 2016-11-10
BR112017023378A2 (pt) 2018-07-24
JP2018515083A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
GB201521858D0 (en) Small molecules
GB201517101D0 (en) Mixed-reality system
GB201501510D0 (en) System
EP3283752C0 (en) FLUID SUPPLY SYSTEM
HK1250370A1 (zh) 基於硼替佐米的遞送系統
PT3073021T (pt) Sistema de conexão
GB201504553D0 (en) Pumps
SG10201508055YA (en) Transaction system
SG10202100138RA (en) Humidification system
HK1250991A1 (zh) Iii型分泌系統靶向分子
ZA201705600B (en) Track-module bogie-suspension system
GB201804730D0 (en) Connector system
GB201517276D0 (en) System
GB2554824B (en) Connector system
IL260137B (en) Irrigation system
GB201500702D0 (en) Alignment aid
GB201413046D0 (en) Fluid-heating system
PT3379987T (pt) Sistema de fixação de recipiente
GB201514541D0 (en) System
ZA201708627B (en) Pump system
GB201514955D0 (en) Paving System
GB201517654D0 (en) Object delivery system
GB201514001D0 (en) Pumps
SI3467183T1 (sl) Kompakten dozirni sistem
GB201522636D0 (en) Delivery system

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE STATE OF INCORPORATION

Effective date: 20240806